SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to ivabradine, up to 10 mg twice daily (n = 9,550) versus placebo (n = 9,552). Results CV death or MI: 6.8% of the ivabradine group vs. 6.4% of the placebo group (p = 0.20) Cardiovascular death: 3.4% vs. 3.2% (p = 0.25), respectively MI: 3.7% vs. 3.5% (p = 0.60), respectively Hospitalization for heart failure: 2.3% vs. 1.9% (p = 0.07), respectively (p = 0.20) % 6.8 6.4 Conclusions Among patients with stable coronary artery disease without clinical heart failure, the use of ivabradine, in addition to standard medical therapy, did not reduce adverse cardiovascular events compared with placebo Ivabradine Placebo Fox K, et al. N Engl J Med 2014;371:1091-9